Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum.
Nakaya A, Shibayama H, Nakatani E, Shimura Y, Kosugi S, Tanaka H, Fuchida SI, Kanda J, Uoshima N, Kaneko H, Imada K, Ohta K, Ito T, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Nakaya A, et al. Among authors: yoshihara s. EJHaem. 2021 Oct 20;2(4):765-773. doi: 10.1002/jha2.284. eCollection 2021 Nov. EJHaem. 2021. PMID: 35845216 Free PMC article.
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment.
Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S; DADI Trial Group, Japan. Okada M, et al. Among authors: yoshihara s. Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.e1. doi: 10.1016/j.clml.2018.03.004. Epub 2018 Mar 15. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29610029 Free article. Clinical Trial.
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry.
Nakaya A, Kohara T, Shibayama H, Onda Y, Kanda J, Kaneko H, Imada K, Kida T, Kosugi S, Ishikawa J, Yamamura R, Shimazu Y, Tanaka H, Fuchida SI, Shimura Y, Kiyota M, Wada K, Ito T, Uoshima N, Yagi H, Yoshihara S, Ohta K, Shimazaki C, Hino M, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S; Kansai Myeloma Forum Investigators. Nakaya A, et al. Among authors: yoshihara s. Int J Hematol. 2020 Oct;112(4):435-438. doi: 10.1007/s12185-020-02996-6. Epub 2020 Sep 21. Int J Hematol. 2020. PMID: 32959221
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis.
Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Takakuwa T, et al. Among authors: yoshihara s. Eur J Haematol. 2021 Apr;106(4):555-562. doi: 10.1111/ejh.13586. Epub 2021 Jan 31. Eur J Haematol. 2021. PMID: 33476404
Expression of activated integrin β7 in multiple myeloma patients.
Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, Shimomura Y, Hanamura I, Fuji S, Minauchi K, Kuroda J, Suzuki R, Nishimura N, Uoshima N, Nakamae H, Kawano Y, Mizuno I, Gomyo H, Suzuki K, Ozaki S, Nakamura S, Imai Y, Kizaki M, Negoro E, Handa H, Iida S. Hosen N, et al. Among authors: yoshihara s. Int J Hematol. 2021 Jul;114(1):3-7. doi: 10.1007/s12185-021-03162-2. Epub 2021 May 17. Int J Hematol. 2021. PMID: 33999338
A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.
Jo T, Yoshihara S, Hada A, Arai Y, Kitawaki T, Ikemoto J, Onomoto H, Sugiyama H, Yoshihara K, Obi N, Matsui K, Niwa N, Nakagawa Y, Kanda J, Kondo T, Saida S, Kato I, Hiramatsu H, Adachi S, Takita J, Takaori-Kondo A, Nagao M. Jo T, et al. Among authors: yoshihara s, yoshihara k. Transplant Cell Ther. 2022 Jul;28(7):365.e1-365.e7. doi: 10.1016/j.jtct.2022.04.013. Epub 2022 Apr 20. Transplant Cell Ther. 2022. PMID: 35460928 Free article.
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Onda Y, et al. Among authors: yoshihara s. Ther Adv Hematol. 2022 Jun 24;13:20406207221104584. doi: 10.1177/20406207221104584. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35785245 Free PMC article.
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide.
Shimazu Y, Kanda J, Kaneko H, Imada K, Yamamura R, Kosugi S, Shimura Y, Ito T, Fuchida SI, Uchiyama H, Fukushima K, Yoshihara S, Hanamoto H, Tanaka H, Uoshima N, Ohta K, Yagi H, Shibayama H, Onda Y, Tanaka Y, Adachi Y, Matsuda M, Iida M, Miyoshi T, Matsui T, Takahashi R, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Shimazu Y, et al. Among authors: yoshihara s. Ther Adv Hematol. 2022 Dec 13;13:20406207221142487. doi: 10.1177/20406207221142487. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36530751 Free PMC article.
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin.
Shimazu Y, Kanda J, Kosugi S, Ito T, Kaneko H, Imada K, Shimura Y, Fuchida SI, Fukushima K, Tanaka H, Yoshihara S, Ohta K, Uoshima N, Yagi H, Shibayama H, Yamamura R, Tanaka Y, Uchiyama H, Onda Y, Adachi Y, Hanamoto H, Takahashi R, Matsuda M, Miyoshi T, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J. Shimazu Y, et al. Among authors: yoshihara s. Sci Rep. 2023 Mar 29;13(1):5159. doi: 10.1038/s41598-023-32426-6. Sci Rep. 2023. PMID: 36991096 Free PMC article.
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.
Shimura Y, Shibayama H, Nakaya A, Yamamura R, Imada K, Kaneko H, Hanamoto H, Fuchida SI, Tanaka H, Kosugi S, Kiyota M, Matsui T, Kanda J, Iida M, Matsuda M, Uoshima N, Shibano M, Karasuno T, Hamada T, Ohta K, Ito T, Yagi H, Yoshihara S, Shimazaki C, Nomura S, Hino M, Takaori-Kondo A, Matsumura I, Kanakura Y, Kuroda J. Shimura Y, et al. Among authors: yoshihara s. Int J Hematol. 2023 Nov;118(5):609-617. doi: 10.1007/s12185-023-03653-4. Epub 2023 Sep 5. Int J Hematol. 2023. PMID: 37668833
673 results